+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Recent advances in post-kala-azar dermal leishmaniasis



Recent advances in post-kala-azar dermal leishmaniasis



Current Opinion in Infectious Diseases 24(5): 418-422



Post-kala-azar dermal leishmaniasis (PKDL) is a challenge for clinicians and researchers, because its burden is poorly investigated and pathogenesis is disputable. However, recent studies contributed to understanding of the pathogenesis of PKDL especially its association with host immunological factors, and also how to improve its diagnosis and treatment. This review focuses on recent advances in diagnosis, new insights into pathogenesis and case management. Information regarding the burden of PKDL, especially in Bangladesh, is now available. Association between skin parasite burden and different clinical forms of PKDL has been explored. The diagnostic importance of detection of Leishmania donovani DNA in the peripheral blood buffy coat and in skin specimens by PCR has been studied. Variable effects of different antileishmanial drugs on immune response have been observed. Finally, high efficacy of miltefosine for treatment of PKDL has been demonstrated. The incidence of PKDL is reducing in India after introduction of miltefosine and amphotericin B for treatment of visceral leishmaniasis. It remains higher in Bangladesh and in Sudan. Parasite burden is higher in nodular and papular forms of PKDL compared to the macular form of the disease. The demonstration of Leishmania DNA in peripheral blood buffy coat and in skin specimens can help to diagnose 40-75% clinically suspected PKDL individuals. An initial cure rate of 95% has been achieved with miltefosine for treatment of PKDL. However, the efficacy of combination therapy should be explored to reduce the treatment duration and hence to improve treatment compliance.

(PDF emailed within 0-6 h: $19.90)

Accession: 055398448

Download citation: RISBibTeXText

PMID: 21885919

DOI: 10.1097/QCO.0b013e32834a8ba1


Related references

Study on the safety and efficacy of miltefosine for the treatment of children and adolescents with post-kala-azar dermal leishmaniasis in Bangladesh, and an association of serum vitamin E and exposure to arsenic with post-kala-azar dermal leishmaniasis: an open clinical trial and case-control study protocol. Bmj Open 6(5): E010050-E010050, 2016

Post-kala-azar dermal leishmaniasis and visceral leishmaniasis in a child--or is it para-kala-azar dermal leishmaniasis?. International Journal of Dermatology 48(9): 1027-1028, 2009

Post-kala-azar dermal leishmaniasis: recent developments. International Journal of Dermatology 50(9): 1099-1108, 2012

Studies on the immunology and serology of leishmaniasis part 9 serological investigation of the parasites of indian kala azar and indian post kala azar dermal leishmaniasis. Transactions of the Royal Society of Tropical Medicine & Hygiene 67(1): 125-129, 1973

Epidemiological, clinical and therapeutic features of Bihar kala-azar (including post kala-azar dermal leishmaniasis). Transactions of the Royal Society of Tropical Medicine and Hygiene 78(3): 391-398, 1984

Insights into the possible role of IFNG and IFNGR1 in Kala-azar and Post Kala-azar Dermal Leishmaniasis in Sudanese patients. Bmc Infectious Diseases 14(): 662-662, 2015

Spectrum of skin lesions of post-kala-azar dermal leishmaniasis in kala-azar endemic areas of Bangladesh. Mymensingh Medical Journal 21(3): 529-532, 2012

Immunoglobulin G subclass-specific antileishmanial antibody responses in Indian kala-azar and post-kala-azar dermal leishmaniasis. Clinical and Diagnostic Laboratory Immunology 2(3): 291-296, 1995

Modulation of the cell-mediated immune response in kala-azar and post-kala-azar dermal leishmaniasis in relation to chemotherapy. Annals of Tropical Medicine and Parasitology 82(1): 27-34, 1988

DNA polymorphism assay distinguishes isolates of Leishmania donovani that cause kala-azar from those that cause post-kala-azar dermal leishmaniasis in humans. Journal of Clinical Microbiology il; 42(4): 1739-1741, 2004

Ten years of kala-azar in west Bengal, Part I. Did post-kala-azar dermal leishmaniasis initiate the outbreak in 24-Parganas?. Bulletin of the World Health Organization 70(3): 341-346, 1992

Observation on antigenic differentiation of leishmania parasites of kala-azar and post-kala-azar dermal leishmaniasis. Annals of Biochemistry and Experimental Medicine 21: 105-108, 1961

Cell-mediated immune response in Indian kala azar and post-kala azar dermal leishmaniasis. Infection and immunity 42(2): 702-707, 1983